Anika Therapeutics, Inc.

NASDAQ:ANIK

Medical - Devices

Healthcare
$13.62 -0.39%

-$0.06 today

Market cap
$182.44M
Beta
0.23
P/E (TTM)
-17.3
EPS (TTM)
-$0.82
52W Low $7.87High $16.24

Volume 0.12M

Average 0.11M

ANIK Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Anika Therapeutics, Inc.NASDAQ: ANIK

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables rises 17.2% from a year ago

Net receivables stood at $25.77M at the end of Q1 FY2026, up 17.2% from a year earlier and up 8.8% from the prior quarter. Over 3 fiscal years it compounded at -11.9% a year.

Context

  • Net receivables amounted to 14.4% of total assets at the end of Q1 FY2026, up 2.8 pp from a year earlier.
  • Net receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +17.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$25.77M+8.8% QoQ
Last fiscal yearDec 2025
$23.69M+0.4% YoY
Year agoMar 2025
$21.99M+17.2% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.2%——
1 year+0.4%——
3-year CAGR-11.9%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
23.69M USD
Year-over-year change
+0.4%
4-year CAGR
-5.6%

Net Receivables vs competitors

How ANIK compares with its peers on the latest reported figures

  • ANIK's Mar 2026 net receivables of $25.77M is the highest of the 9 companies compared; the peer median is $4.71M.
  • Its year-over-year change of +17.2% is the 5th highest of 8, against a peer median of +20.2%.
  • Net receivables amounts to 14.4% of total assets for ANIK, versus a peer median of 5.0%.
ANIK Competitors Peer median
Net Receivables for ANIK and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ANIKAnika Therapeutics, Inc.Mar 2026$25.77M +17.2%-11.9%14.4%
OWLTOwlet, Inc.Mar 2026$19.86M +20.2%+12.8%22.9%
APYXApyx Medical CorporationMar 2026$12.76M +9.5%-2.8%20.2%
RPIDRapid Micro Biosystems, Inc.Mar 2026$6.49M +43.3%-15.7%10.4%
LNSRLENSAR, Inc.Mar 2026$5.18M -28.4%+0.7%7.8%
MXCTMaxCyte, Inc.Mar 2026$4.25M -23.1%-32.1%2.2%
LUCDLucid Diagnostics Inc.Mar 2026$689K +1029.5%+235.7%2.0%
AVRAnteris Technologies Global Corp.Mar 2026$231K +22.2%-72.4%0.1%
ANIXAnixa Biosciences, Inc.Apr 2026$56K ——0.4%
Peer median (excluding ANIK) $4.71M+20.2%-2.8%5.0%

Competitors are the stored peer set for ANIK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents94.39M86.33M68.74M55.63M57.48M
Short-term Investments00000
Net Receivables29.84M34.63M26.36M23.59M23.69M
Inventory36.01M39.77M24.43M23.81M18.79M
Other Current Assets0043.78M10.62M3.4M
Total Current Assets168.53M169.55M163.31M113.65M103.36M
Property, Plant & Equipment (Net)68.56M78.98M65M64.68M66.26M
Goodwill7.78M7.34M7.57M7.13M8.05M
Intangible Assets82.38M74.6M2.58M2.49M1.65M
Long-term Investments00000
Tax Assets01.45M1.49M1.18M1.28M
Other Non-current Assets20.29M17.22M30.69M13.62M9.67M
Total Non-current Assets179.01M179.58M107.32M89.09M86.91M
Total Assets347.54M349.13M270.63M202.74M190.27M
Account Payables7.63M9.07M6.19M5.62M6.04M
Short-term Debt00000
Tax Payables0810K1.24M63K0
Deferred Revenue00000
Other Current Liabilities13.84M11.3M18.73M12.16M11.11M
Total Current Liabilities29.8M27.91M31.06M23.31M21.91M
Long-term Debt000024.2M
Deferred Tax Liabilities10.16M6.44M000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities1.26M398K1.39M1.43M701K
Total Non-current Liabilities30.66M35.65M27.31M25.45M24.9M
Total Liabilities60.45M63.57M58.37M48.75M46.81M
Common Stock144K146K147K144K139K
Retained Earnings225.58M210.72M128.05M71.67M60.79M
Accumulated OCI(5.72M)(6.44M)(5.94M)(6.78M)(4.96M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity287.09M285.56M212.27M153.99M143.47M
Total Debt20.95M30.89M27.74M25.93M26.25M
Net Debt(73.43M)(55.44M)(41M)(29.7M)(31.23M)

Anika Therapeutics, Inc.

NASDAQ:ANIK

Intrinsic Alpha fair value

Locked

Current Price

$13.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.